Avagliano Mark
- SEC CIK
- 0001783503
No open-market purchases or sales filed in the past year.
Current role at each company
- GTHX G1 Therapeutics, Inc.Chief Business Officeras of Sep 18, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Avagliano Mark as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 8, 2024 (view filing) | Jul 5 | 3 days | Avagliano MarkChief Business Officer | SSale | −2.64K | $2.51 | −$6.62K | −1.1%242.0K after | |
| May 15, 2024 (view filing) | May 13 | 2 days | Avagliano MarkChief Business Officer | SSale | −8.15K | $4.79 | −$39.0K | −3.7%209.7K after | |
| Jan 8, 2024 (view filing) | Jan 3-4 | 5 daysLate | Avagliano MarkChief Business Officer | SSale | −4.08K | $3.09 | −$12.6K | −3.3%117.8K after | 3 lots |
| Jan 5, 2022 (view filing) | Jan 5 | Same day | Avagliano MarkChief Business Officer | SSale | −1.45K | $10.61 | −$15.3K | −6.3%21.6K after |